海思科(002653.SZ):擬2.69億元轉讓HSK3486乳狀注射液鎮靜/麻醉藥物在中國內地以外專有技術所有權
格隆匯 12 月 1日丨海思科(002653.SZ)公佈,公司全資子公司四川海思科製藥有限公司(“四川海思科”)擬與公司控股四級子公司HAISCO INNOVATIVE PHARMACEUTICAL PTE. LTD.(“海思科新加坡公司”)簽訂《技術轉讓合同》,四川海思科擬將其擁有的一項HSK3486乳狀注射液鎮靜/麻醉藥物在中國內地以外市場(含港澳台)的專有技術所有權轉讓給海思科新加坡公司,轉讓價格為人民幣約2.69億元。
HSK3486是四川海思科開發的全新的具有自主知識產權的靜脈麻醉藥物,擬用於手術全麻誘導/維持、內鏡診療的鎮靜/麻醉、ICU鎮靜等適應症。按我國新化學藥品註冊分類規定,其藥品註冊分類為化藥1類。
四川海思科製藥有限公司擬轉讓HSK3486乳狀注射液鎮靜/麻醉藥物在中國內地以外市場(含港澳台)的專有技術所有權,含專利權、專利申請權和技術祕密,該資產的賬面價值為人民幣6,845萬元(未經審計)。
四川海思科出售HSK3486乳狀注射液鎮靜/麻醉藥物在中國內地以外市場(含港澳台)的專有技術所有權給海思科新加坡公司,是為了更好地推動公司創新藥在海外的運營,未來該產品在境外的臨牀試驗組織和投入、以及商業化都將由海思科新加坡公司牽頭負責。
四川海思科為公司全資子公司,海思科新加坡公司為公司控股公司,其財務報表已納入公司的合併報表範圍內,此次股權轉讓對公司的正常經營和財務狀況均不構成實質性影響,不會損害公司及股東利益,符合公司發展需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.